Clinical Research

Biohaven Therapeutics Ltd.

Address
215 Church Street

Sponsor Overview

assignment
6
sponsored trials
science
2
molecules
location_city
191
research centres
public
18
countries
person_search
221
investigators

Specializations

Epilepsy and seizure disorders

Biohaven Therapeutics Ltd. funds clinical research in refractory focal onset epilepsy and idiopathic generalized epilepsy with generalized tonic-clonic seizures, with attention to seizure control, treatment response, and overall safety in adults living with difficult-to-manage epileptic conditions.

  • Refractory focal onset epilepsy
  • Idiopathic generalized epilepsy with generalized tonic-clonic seizures
  • Antiseizure therapy

The sponsor’s epilepsy portfolio reflects interest in therapies aimed at reducing seizure burden and addressing unmet needs in chronic neurological disorders.

Parkinson’s disease

The company also supports studies in early Parkinson’s disease, focusing on clinical outcomes linked to motor and functional impairment and the potential to slow worsening in everyday activities.

  • Early Parkinson’s disease
  • Movement disorder
  • Functional decline

This area of interest places emphasis on neurodegenerative disease management and symptom-related disability.

Pain and analgesic research

Biohaven Therapeutics Ltd. has research activity in pain treatment, including evaluation of candidate therapies for analgesic use and tolerability in healthy participants, indicating interest in both pain relief and central nervous system-related pharmacology.

  • Pain
  • Analgesic therapy
  • Central nervous system pharmacology

The sponsor’s pain-related work connects to broader efforts in neurology and symptom management.

Therapeutic development in neurology

Across its funded studies, the sponsor’s clinical research landscape is centered on neurological disease areas where treatment options are limited, including epilepsy, Parkinson’s disease, and pain-related conditions.

  • Neurological disorders
  • Seizure disorders
  • Neurodegenerative disease

Its portfolio includes work relevant to adult patients with chronic conditions requiring sustained therapeutic management.

Sponsored Trials

Trial Name Country Status
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s DiseaseAustria AustriaBelgium BelgiumCzechia CzechiaFrance FranceGermany GermanyItaly ItalyPoland PolandPortugal PortugalSpain SpainThe Netherlands The NetherlandsNot Yet Recruiting
Efficacy and Safety Evaluation of BHV-7000 as Adjunctive Therapy in Adults with Refractory Focal Onset Epilepsy: A Randomized, Double-Blind, Placebo-Controlled StudyAustria AustriaBelgium BelgiumCroatia CroatiaCzechia CzechiaFrance FranceHungary HungaryPoland PolandSlovenia SloveniaThe Netherlands The NetherlandsRecruiting
Efficacy and Safety Evaluation of BHV-7000 in Adults with Refractory Focal Onset Epilepsy: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled StudyDenmark DenmarkFinland FinlandGermany GermanyGreece GreeceHungary HungaryItaly ItalyPoland PolandPortugal PortugalRomania RomaniaSlovakia SlovakiaSpain SpainNot Recruiting
Evaluation of BHV-7000 as Adjunctive Therapy in Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures: A Randomized, Double-blind, Placebo-controlled StudyAustria AustriaBelgium BelgiumCroatia CroatiaFinland FinlandFrance FranceGermany GermanyItaly ItalyPoland PolandPortugal PortugalSpain SpainThe Netherlands The NetherlandsNot Recruiting
Evaluation of the Efficacy, Safety, and Tolerability of BHV-2100 and BHV-7000 in the Management of Pain in Healthy Male SubjectsGermany GermanyNot Recruiting
Evaluation of the Safety and Tolerability of BHV-7000 in Adults with Refractory Focal Onset Epilepsy: A Phase 2 Multicenter StudyAustria AustriaBelgium BelgiumCroatia CroatiaCzechia CzechiaDenmark DenmarkFinland FinlandFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyPoland PolandPortugal PortugalRomania RomaniaSlovakia SlovakiaSlovenia SloveniaSpain SpainThe Netherlands The NetherlandsRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 2 total (50% not shared with other sponsors)

This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
56%
Return partnership rate
107 of 191 sites collaborated multiple times

This sponsor has worked with 191 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Nervous System Diseases6 trials
    449 other sponsors

Partnered Research Centres

191 centres
location_city
assignment57
Aix Marseille University
Address
264 Boulevard de Saint Pierre, 13005 Marseille
Learn morearrow_forward
location_city
assignment2
Alexianer St Joseph Berlin-Weissensee GmbH
Address
Gartenstrasse 1, Weissensee, 13088 Berlin
Learn morearrow_forward
location_city
assignment163
Algemeen Ziekenhuis Groeninge
Address
President Kennedylaan 4, 8500 Kortrijk
Learn morearrow_forward
location_city
assignment86
Area De Salud De Burgos Y Soria
Address
Avenida De Las Islas Baleares 3, 09006 Burgos
Learn morearrow_forward
location_city
assignment392
Azienda Ospedaliera di Padova
Address
Via Nicolo' Giustiniani 2, 35128 Padua
Learn morearrow_forward
location_city
assignment560
Azienda Ospedaliera Universitaria Federico II Di Napoli
Address
Via Sergio Pansini 5, 80131 Naples
Learn morearrow_forward
Page 1 of 32

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Biohaven Therapeutics Ltd..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.